source
- Merck's anti-TL1A antibody scores a win in hidradenitis suppurativa, fails in SSc-ILDMerck said the anti-TL1A antibody at the center of its $10.8 billion Prometheus Biosciences acquisition failed a mid-stage trial for a rare type of lung disease, while also succeeding in a separate…Endpoints · 4h ago↗ source
- Merck’s $11B anti-TL1A bet delivers 1 win, 1 loss in midphase inflammatory disease trialsA phase 2 trial of Merck & Co.’s anti-TL1A monoclonal antibody has missed its primary endpoint, closing off one avenue for expansion of an asset acquired in a $10.8 billion takeover. The setback wa…Fierce Biotech · 11h ago↗ source
- Analyst warns AstraZeneca-BMS merger could spark regulatory hurdles and job cutsAngus Liu writes an editorial warning that talks of a merger between AstraZeneca and Bristol Myers Squibb could create more problems than benefits. He notes that the two companies have only discuss…